Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis

Yanming Wu, Zhao Zhang, Mauro E. Cenciarini, Cecilia J. Proietti, Matias Amasino, Tao Hong, Mei Yang, Yiji Liao, Huai Chin Chiang, Virginia G. Kaklamani, Rinath Jeselsohn, Ratna K Vadlamudi, Hui-ming Huang, Rong Li, Carmine De Angelis, Xiaoyong Fu, Patricia V. Elizalde, Rachel Schiff, Myles Brown, Kexin Xu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes in favor of the refractory phenotypes. Here we discover that tamoxifen resistance in breast cancer is driven by a regulatory axis consisting of a master transcription factor, its cofactor, and an epigenetic regulator. The oncogenic histone methyltransferase EZH2 conferred tamoxifen resistance by silencing the expression of the estrogen receptor a (ERa) cofactor GREB1. In clinical specimens, induction of DNA methylation of a particular CpG-enriched region at the GREB1 promoter negatively correlated with GREB1 levels and cell sensitivity to endocrine agents. GREB1 also ensured proper cellular reactions to different ligands by recruiting distinct sets of ERa cofactors to cis-regulatory elements, which explains the contradictory biological effects of GREB1 on breast cancer cell growth in response to estrogen or antiestrogen. In refractory cells, EZH2-dependent repression of GREB1 triggered chromatin reallocation of ERa coregulators, converting the antiestrogen into an agonist. In clinical specimens from patients receiving adjuvant tamoxifen treatment, expression levels of EZH2 and GREB1 were correlated negatively, and taken together better predicted patient responses to endocrine therapy. Overall, our work suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program. Significance: This study suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program defined within.

Original languageEnglish (US)
Pages (from-to)671-684
Number of pages14
JournalCancer Research
Volume78
Issue number3
DOIs
StatePublished - Feb 1 2018

Fingerprint

Tamoxifen
Epigenomics
Estrogen Receptors
Breast Neoplasms
Estrogen Receptor Modulators
DNA Methylation
Transcriptome
Chromatin
Estrogens
Transcription Factors
Therapeutics
Ligands
Phenotype
Growth
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis. / Wu, Yanming; Zhang, Zhao; Cenciarini, Mauro E.; Proietti, Cecilia J.; Amasino, Matias; Hong, Tao; Yang, Mei; Liao, Yiji; Chiang, Huai Chin; Kaklamani, Virginia G.; Jeselsohn, Rinath; Vadlamudi, Ratna K; Huang, Hui-ming; Li, Rong; De Angelis, Carmine; Fu, Xiaoyong; Elizalde, Patricia V.; Schiff, Rachel; Brown, Myles; Xu, Kexin.

In: Cancer Research, Vol. 78, No. 3, 01.02.2018, p. 671-684.

Research output: Contribution to journalArticle

Wu, Y, Zhang, Z, Cenciarini, ME, Proietti, CJ, Amasino, M, Hong, T, Yang, M, Liao, Y, Chiang, HC, Kaklamani, VG, Jeselsohn, R, Vadlamudi, RK, Huang, H, Li, R, De Angelis, C, Fu, X, Elizalde, PV, Schiff, R, Brown, M & Xu, K 2018, 'Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis', Cancer Research, vol. 78, no. 3, pp. 671-684. https://doi.org/10.1158/0008-5472.CAN-17-1327
Wu, Yanming ; Zhang, Zhao ; Cenciarini, Mauro E. ; Proietti, Cecilia J. ; Amasino, Matias ; Hong, Tao ; Yang, Mei ; Liao, Yiji ; Chiang, Huai Chin ; Kaklamani, Virginia G. ; Jeselsohn, Rinath ; Vadlamudi, Ratna K ; Huang, Hui-ming ; Li, Rong ; De Angelis, Carmine ; Fu, Xiaoyong ; Elizalde, Patricia V. ; Schiff, Rachel ; Brown, Myles ; Xu, Kexin. / Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis. In: Cancer Research. 2018 ; Vol. 78, No. 3. pp. 671-684.
@article{027fa8f278cb465abf7828c664cc3663,
title = "Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis",
abstract = "Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes in favor of the refractory phenotypes. Here we discover that tamoxifen resistance in breast cancer is driven by a regulatory axis consisting of a master transcription factor, its cofactor, and an epigenetic regulator. The oncogenic histone methyltransferase EZH2 conferred tamoxifen resistance by silencing the expression of the estrogen receptor a (ERa) cofactor GREB1. In clinical specimens, induction of DNA methylation of a particular CpG-enriched region at the GREB1 promoter negatively correlated with GREB1 levels and cell sensitivity to endocrine agents. GREB1 also ensured proper cellular reactions to different ligands by recruiting distinct sets of ERa cofactors to cis-regulatory elements, which explains the contradictory biological effects of GREB1 on breast cancer cell growth in response to estrogen or antiestrogen. In refractory cells, EZH2-dependent repression of GREB1 triggered chromatin reallocation of ERa coregulators, converting the antiestrogen into an agonist. In clinical specimens from patients receiving adjuvant tamoxifen treatment, expression levels of EZH2 and GREB1 were correlated negatively, and taken together better predicted patient responses to endocrine therapy. Overall, our work suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program. Significance: This study suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program defined within.",
author = "Yanming Wu and Zhao Zhang and Cenciarini, {Mauro E.} and Proietti, {Cecilia J.} and Matias Amasino and Tao Hong and Mei Yang and Yiji Liao and Chiang, {Huai Chin} and Kaklamani, {Virginia G.} and Rinath Jeselsohn and Vadlamudi, {Ratna K} and Hui-ming Huang and Rong Li and {De Angelis}, Carmine and Xiaoyong Fu and Elizalde, {Patricia V.} and Rachel Schiff and Myles Brown and Kexin Xu",
year = "2018",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-17-1327",
language = "English (US)",
volume = "78",
pages = "671--684",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis

AU - Wu, Yanming

AU - Zhang, Zhao

AU - Cenciarini, Mauro E.

AU - Proietti, Cecilia J.

AU - Amasino, Matias

AU - Hong, Tao

AU - Yang, Mei

AU - Liao, Yiji

AU - Chiang, Huai Chin

AU - Kaklamani, Virginia G.

AU - Jeselsohn, Rinath

AU - Vadlamudi, Ratna K

AU - Huang, Hui-ming

AU - Li, Rong

AU - De Angelis, Carmine

AU - Fu, Xiaoyong

AU - Elizalde, Patricia V.

AU - Schiff, Rachel

AU - Brown, Myles

AU - Xu, Kexin

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes in favor of the refractory phenotypes. Here we discover that tamoxifen resistance in breast cancer is driven by a regulatory axis consisting of a master transcription factor, its cofactor, and an epigenetic regulator. The oncogenic histone methyltransferase EZH2 conferred tamoxifen resistance by silencing the expression of the estrogen receptor a (ERa) cofactor GREB1. In clinical specimens, induction of DNA methylation of a particular CpG-enriched region at the GREB1 promoter negatively correlated with GREB1 levels and cell sensitivity to endocrine agents. GREB1 also ensured proper cellular reactions to different ligands by recruiting distinct sets of ERa cofactors to cis-regulatory elements, which explains the contradictory biological effects of GREB1 on breast cancer cell growth in response to estrogen or antiestrogen. In refractory cells, EZH2-dependent repression of GREB1 triggered chromatin reallocation of ERa coregulators, converting the antiestrogen into an agonist. In clinical specimens from patients receiving adjuvant tamoxifen treatment, expression levels of EZH2 and GREB1 were correlated negatively, and taken together better predicted patient responses to endocrine therapy. Overall, our work suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program. Significance: This study suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program defined within.

AB - Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes in favor of the refractory phenotypes. Here we discover that tamoxifen resistance in breast cancer is driven by a regulatory axis consisting of a master transcription factor, its cofactor, and an epigenetic regulator. The oncogenic histone methyltransferase EZH2 conferred tamoxifen resistance by silencing the expression of the estrogen receptor a (ERa) cofactor GREB1. In clinical specimens, induction of DNA methylation of a particular CpG-enriched region at the GREB1 promoter negatively correlated with GREB1 levels and cell sensitivity to endocrine agents. GREB1 also ensured proper cellular reactions to different ligands by recruiting distinct sets of ERa cofactors to cis-regulatory elements, which explains the contradictory biological effects of GREB1 on breast cancer cell growth in response to estrogen or antiestrogen. In refractory cells, EZH2-dependent repression of GREB1 triggered chromatin reallocation of ERa coregulators, converting the antiestrogen into an agonist. In clinical specimens from patients receiving adjuvant tamoxifen treatment, expression levels of EZH2 and GREB1 were correlated negatively, and taken together better predicted patient responses to endocrine therapy. Overall, our work suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program. Significance: This study suggests a new strategy to overcome endocrine resistance in metastatic breast cancer by targeting a particular epigenetic program defined within.

UR - http://www.scopus.com/inward/record.url?scp=85041470633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041470633&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-1327

DO - 10.1158/0008-5472.CAN-17-1327

M3 - Article

C2 - 29212856

AN - SCOPUS:85041470633

VL - 78

SP - 671

EP - 684

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -